Diphenhydramine Hydrochloride Injection, Solution
NDC Package 51662-1374-1
Package Information
Diphenhydramine Hydrochloride injection is diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical.AntihistaminicFor amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.Motion SicknessFor active treatment of motion sickness.AntiparkinsonismFor use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents. This formulation utilizes a injection, solution delivery system. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1374 and is authorized under FDA application ANDA040466.
Identification & Billing
- RxCUI: 1723740 - diphenhydrAMINE HCl 50 MG in 1 ML Injection
- RxCUI: 1723740 - 1 ML diphenhydramine hydrochloride 50 MG/ML Injection
- RxCUI: 1723740 - diphenhydramine HCl 50 MG per 1 ML Injection
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Intravenous - Administration within or into a vein or veins.
Regulatory & Marketing
Hierarchy Structure
- 51662 - Hf Acquisition Co Llc, Dba Healthfirst
- 51662-1374 - Diphenhydramine Hydrochloride
- 51662-1374-1 - 1 mL in 1 VIAL, SINGLE-DOSE
- 51662-1374 - Diphenhydramine Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51662-1374-1 identifies a specific commercial package of 1 ml in 1 vial, single-dose of Diphenhydramine Hydrochloride, a human prescription drug labeled by Hf Acquisition Co Llc, Dba Healthfirst. This injection, solution is formulated for intramuscular; intravenous use and contains diphenhydramine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on November 11, 2019. The current certification is valid through December 31, 2027.
How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662137401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.